{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T08:39:17Z","timestamp":1792917557850,"version":"4.5.0"},"reference-count":222,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40265-024-02128-y","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T09:54:53Z","timestamp":1738058093000},"page":"215-230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7903-3993","authenticated-orcid":false,"given":"Mellar","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"issue":"4","key":"2128_CR1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1476-5381.1977.tb07533.x","volume":"60","author":"A Cowan","year":"1977","unstructured":"Cowan A, Doxey JC, Harry EJ. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol. 1977;60(4):547\u201354.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"2128_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1476-5381.1977.tb07532.x","volume":"60","author":"A Cowan","year":"1977","unstructured":"Cowan A, Lewis JW, Macfarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol. 1977;60(4):537\u201345.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2128_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.bja.2023.10.041","volume":"132","author":"DSK Samways","year":"2024","unstructured":"Samways DSK. Clarifying intrinsic efficacy, partial agonism, and full agonism: the case of buprenorphine. Br J Anaesth. 2024;132(2):431\u20132.","journal-title":"Br J Anaesth"},{"key":"2128_CR4","first-page":"3","volume":"133","author":"A Cowan","year":"2003","unstructured":"Cowan A. Buprenorphine: new pharmacological aspects. Int J Clin Pract Suppl. 2003;133:3\u20138 (discussion 23-4).","journal-title":"Int J Clin Pract Suppl"},{"issue":"8","key":"2128_CR5","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s00520-024-08710-0","volume":"32","author":"MP Davis","year":"2024","unstructured":"Davis MP, Davies A, McPherson ML, Reddy A, Paice JA, Roeland E, et al. Opioid analgesic dose and route conversion ratio studies: a scoping review to inform an eDelphi guideline. Support Care Cancer. 2024;32(8):542.","journal-title":"Support Care Cancer"},{"issue":"5","key":"2128_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ejpain.2005.02.002","volume":"9","author":"B Kogel","year":"2005","unstructured":"Kogel B, Christoph T, Strassburger W, Friderichs E. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur J Pain. 2005;9(5):599\u2013611.","journal-title":"Eur J Pain"},{"issue":"7","key":"2128_CR7","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/AJP.0000000000000144","volume":"31","author":"X Leng","year":"2015","unstructured":"Leng X, Li Z, Lv H, Zheng Y, Liu Y, Dai K, et al. Effectiveness and safety of transdermal buprenorphine versus sustained-release tramadol in patients with moderate to severe musculoskeletal pain: an 8-week, randomized, double-blind, double-dummy, multicenter, active-controlled, noninferiority study. Clin J Pain. 2015;31(7):612\u201320.","journal-title":"Clin J Pain"},{"issue":"12","key":"2128_CR8","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00432-013-1487-0","volume":"139","author":"C Naing","year":"2013","unstructured":"Naing C, Aung K, Racloz V, Yeoh PN. Safety and efficacy of transdermal buprenorphine for the relief of cancer pain. J Cancer Res Clin Oncol. 2013;139(12):1963\u201370.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"2128_CR9","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1185\/03007995.2012.678938","volume":"28","author":"RF Wolff","year":"2012","unstructured":"Wolff RF, Aune D, Truyers C, Hernandez AV, Misso K, Riemsma R, et al. Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Curr Med Res Opin. 2012;28(5):833\u201345.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"2128_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2165\/11536010-000000000-00000","volume":"30","author":"F Magnelli","year":"2010","unstructured":"Magnelli F, Biondi L, Calabria R, Fiore A, Peluso E, Vonella D, et al. Safety and efficacy of buprenorphine\/naloxone in opioid-dependent patients: an Italian observational study. Clin Drug Investig. 2010;30(Suppl 1):21\u20136.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"2128_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jpainsymman.2007.09.011","volume":"36","author":"P Poulain","year":"2008","unstructured":"Poulain P, Denier W, Douma J, Hoerauf K, Samija M, Sopata M, et al. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. J Pain Symptom Manag. 2008;36(2):117\u201325.","journal-title":"J Pain Symptom Manag"},{"issue":"1","key":"2128_CR12","first-page":"115","volume":"2","author":"R Likar","year":"2006","unstructured":"Likar R. Transdermal buprenorphine in the management of persistent pain - safety aspects. Ther Clin Risk Manag. 2006;2(1):115\u201325.","journal-title":"Ther Clin Risk Manag"},{"issue":"882","key":"2128_CR13","first-page":"24","volume":"103","author":"NC Varey","year":"1990","unstructured":"Varey NC. The safety of buprenorphine (Temgesic). N Z Med J. 1990;103(882):24.","journal-title":"N Z Med J"},{"issue":"11","key":"2128_CR14","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.jpain.2023.07.001","volume":"24","author":"B Aguilar","year":"2023","unstructured":"Aguilar B, Penm J, Liu S, Patanwala AE. Efficacy and safety of transdermal buprenorphine for acute postoperative pain: a systematic review and meta-analysis. J Pain. 2023;24(11):1905\u201314.","journal-title":"J Pain"},{"issue":"5","key":"2128_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1533-2500.2008.00205.x","volume":"8","author":"C Barutell","year":"2008","unstructured":"Barutell C, Camba A, Gonzalez-Escalada JR, Rodriguez M, Opioid Group of the Spanish Society for the Study of P. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres\u2014a retrospective multicenter safety and efficacy study. Pain Pract. 2008;8(5):355\u201361.","journal-title":"Pain Pract"},{"issue":"2 Suppl","key":"2128_CR16","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/S0376-8716(03)00061-9","volume":"70","author":"TP Bridge","year":"2003","unstructured":"Bridge TP, Fudala PJ, Herbert S, Leiderman DB. Safety and health policy considerations related to the use of buprenorphine\/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend. 2003;70(2 Suppl):S79-85.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"2128_CR17","first-page":"871","volume":"79","author":"A Canneti","year":"2013","unstructured":"Canneti A, Luzi M, Di Marco P, Cannata F, Pasqualitto F, Spinoglio A, et al. Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients. Minerva Anestesiol. 2013;79(8):871\u201383.","journal-title":"Minerva Anestesiol"},{"issue":"8","key":"2128_CR18","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/add.14636","volume":"114","author":"M Frost","year":"2019","unstructured":"Frost M, Bailey GL, Lintzeris N, Strang J, Dunlop A, Nunes EV, et al. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Addiction. 2019;114(8):1416\u201326.","journal-title":"Addiction"},{"key":"2128_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2147\/JPR.S120170","volume":"10","author":"M Hale","year":"2017","unstructured":"Hale M, Urdaneta V, Kirby MT, Xiang Q, Rauck R. Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids. J Pain Res. 2017;10:233\u201340.","journal-title":"J Pain Res"},{"issue":"3","key":"2128_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/00952990.2021.2003809","volume":"48","author":"MC Hazle","year":"2022","unstructured":"Hazle MC, Saxon AJ, Hill KP. Buprenorphine in safety-sensitive positions. Am J Drug Alcohol Abuse. 2022;48(3):255\u20139.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"15","key":"2128_CR21","doi-asserted-by":"publisher","first-page":"PL285","DOI":"10.1016\/0024-3205(95)00078-X","volume":"56","author":"J Kamei","year":"1995","unstructured":"Kamei J, Saitoh A, Suzuki T, Misawa M, Nagase H, Kasuya Y. Buprenorphine exerts its antinociceptive activity via mu 1-opioid receptors. Life Sci. 1995;56(15):PL285\u201390.","journal-title":"Life Sci"},{"issue":"5","key":"2128_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/clpt.1994.71","volume":"55","author":"SL Walsh","year":"1994","unstructured":"Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569\u201380.","journal-title":"Clin Pharmacol Ther"},{"issue":"2\u20133","key":"2128_CR23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.14740\/jocmr5050","volume":"16","author":"S Bhivandkar","year":"2024","unstructured":"Bhivandkar S, Sarfraz Z, Jain L, Bachu A, Malo PK, Hsu M, et al. Therapeutic potential of buprenorphine in depression: a meta-analysis of current evidence. J Clin Med Res. 2024;16(2\u20133):46\u201355.","journal-title":"J Clin Med Res"},{"issue":"3","key":"2128_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jpainsymman.2004.07.005","volume":"29","author":"RE Johnson","year":"2005","unstructured":"Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manag. 2005;29(3):297\u2013326.","journal-title":"J Pain Symptom Manag"},{"key":"2128_CR25","doi-asserted-by":"publisher","first-page":"100131","DOI":"10.1016\/j.dadr.2023.100131","volume":"6","author":"B Del Pozo","year":"2023","unstructured":"Del Pozo B, Atkins D, Andraka-Christou B, Wightman R, Clark MH, Huynh P, et al. Buprenorphine involvement in opioid overdose deaths: a retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015\u20132021. Drug Alcohol Depend Rep. 2023;6:100131.","journal-title":"Drug Alcohol Depend Rep."},{"issue":"6","key":"2128_CR26","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1111\/j.1471-4159.1982.tb06662.x","volume":"38","author":"JW Villiger","year":"1982","unstructured":"Villiger JW, Taylor KM. Buprenorphine: high-affinity binding to dorsal spinal cord. J Neurochem. 1982;38(6):1771\u20133.","journal-title":"J Neurochem"},{"issue":"26","key":"2128_CR27","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1016\/0024-3205(81)90529-4","volume":"29","author":"JW Villiger","year":"1981","unstructured":"Villiger JW, Taylor KM. Buprenorphine\u202f: characteristics of binding sites in the rat central nervous system. Life Sci. 1981;29(26):2699\u2013708.","journal-title":"Life Sci"},{"issue":"2","key":"2128_CR28","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/bja\/57.2.192","volume":"57","author":"RA Boas","year":"1985","unstructured":"Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth. 1985;57(2):192\u20136.","journal-title":"Br J Anaesth"},{"issue":"2","key":"2128_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1124\/jpet.118.249839","volume":"367","author":"JM Bidlack","year":"2018","unstructured":"Bidlack JM, Knapp BI, Deaver DR, Plotnikava M, Arnelle D, Wonsey AM, et al. In vitro pharmacological characterization of buprenorphine, samidorphan, and combinations being developed as an adjunctive treatment of major depressive disorder. J Pharmacol Exp Ther. 2018;367(2):267\u201381.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2128_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13054-020-2740-y","volume":"24","author":"N Zamani","year":"2020","unstructured":"Zamani N, Buckley NA, Hassanian-Moghaddam H. Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial. Crit Care. 2020;24(1):44.","journal-title":"Crit Care"},{"issue":"6","key":"2128_CR31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.annemergmed.2016.12.024","volume":"69","author":"N Zamani","year":"2017","unstructured":"Zamani N, Hassanian-Moghaddam H. Intravenous buprenorphine: a substitute for naloxone in methadone-overdosed patients? Ann Emerg Med. 2017;69(6):737\u20139.","journal-title":"Ann Emerg Med"},{"issue":"3","key":"2128_CR32","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.toxlet.2014.12.007","volume":"232","author":"N Zamani","year":"2015","unstructured":"Zamani N, Hassanian-Moghaddam H, Bayat AH, Haghparast A, Shadnia S, Rahimi M, et al. Reversal of opioid overdose syndrome in morphine-dependent rats using buprenorphine. Toxicol Lett. 2015;232(3):590\u20134.","journal-title":"Toxicol Lett"},{"issue":"9","key":"2128_CR33","doi-asserted-by":"publisher","first-page":"e156973","DOI":"10.1172\/jci.insight.156973","volume":"7","author":"E Olofsen","year":"2022","unstructured":"Olofsen E, Algera MH, Moss L, Dobbins RL, Groeneveld GJ, van Velzen M, et al. Modeling buprenorphine reduction of fentanyl-induced respiratory depression. JCI Insight. 2022;7(9):e156973.","journal-title":"JCI Insight."},{"issue":"1","key":"2128_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11095-007-9440-z","volume":"25","author":"A Yassen","year":"2008","unstructured":"Yassen A, Olofsen E, Kan J, Dahan A, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm Res. 2008;25(1):183\u201393.","journal-title":"Pharm Res"},{"issue":"1","key":"2128_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/sj.clpt.6100025","volume":"81","author":"A Yassen","year":"2007","unstructured":"Yassen A, Olofsen E, Romberg R, Sarton E, Teppema L, Danhof M, et al. Mechanism-based PK\/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther. 2007;81(1):50\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"2128_CR36","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/dar.13228","volume":"40","author":"B Oakley","year":"2021","unstructured":"Oakley B, Wilson H, Hayes V, Lintzeris N. Managing opioid withdrawal precipitated by buprenorphine with buprenorphine. Drug Alcohol Rev. 2021;40(4):567\u201371.","journal-title":"Drug Alcohol Rev"},{"issue":"2","key":"2128_CR37","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/fampra\/cmab073","volume":"39","author":"THN Quattlebaum","year":"2022","unstructured":"Quattlebaum THN, Kiyokawa M, Murata KA. A case of buprenorphine-precipitated withdrawal managed with high-dose buprenorphine. Fam Pract. 2022;39(2):292\u20134.","journal-title":"Fam Pract"},{"issue":"4","key":"2128_CR38","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/ADM.0000000000000935","volume":"16","author":"H Brogdon","year":"2022","unstructured":"Brogdon H, Facer KL, Cox EJ, Carlson RH Jr, Wurzel JF 3rd. Rapid transition to buprenorphine in a patient with methadone-related QTc interval prolongation. J Addict Med. 2022;16(4):488\u201391.","journal-title":"J Addict Med"},{"issue":"4","key":"2128_CR39","first-page":"56","volume":"5","author":"V Urban","year":"2008","unstructured":"Urban V, Sullivan R. Buprenorphine rescue from naltrexone-induced opioid withdrawal during relatively rapid detoxification from high-dose methadone: a novel approach. Psychiatry (Edgmont). 2008;5(4):56\u20138.","journal-title":"Psychiatry (Edgmont)"},{"issue":"2","key":"2128_CR40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/08897077.2019.1573776","volume":"40","author":"HB Ward","year":"2019","unstructured":"Ward HB, Barnett BS, Suzuki J. Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: a case report. Subst Abus. 2019;40(2):140\u20135.","journal-title":"Subst Abus"},{"issue":"2","key":"2128_CR41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/ADM.0000000000001073","volume":"17","author":"A Randall","year":"2023","unstructured":"Randall A, Hull I, Martin SA. Enhancing patient choice: using self-administered intranasal naloxone for novel rapid buprenorphine initiation. J Addict Med. 2023;17(2):237\u201340.","journal-title":"J Addict Med"},{"issue":"6","key":"2128_CR42","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/ADM.0000000000000675","volume":"14","author":"B Hamata","year":"2020","unstructured":"Hamata B, Griesdale D, Hann J, Rezazadeh-Azar P. Rapid micro-induction of buprenorphine\/naloxone for opioid use disorder in a critically ill intubated patient: a case report. J Addict Med. 2020;14(6):514\u20137.","journal-title":"J Addict Med"},{"issue":"2","key":"2128_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1213\/XAA.0000000000001138","volume":"14","author":"DS Lee","year":"2020","unstructured":"Lee DS, Hann JE, Klaire SS, Nikoo M, Negraeff MD, Rezazadeh-Azar P. Rapid induction of buprenorphine\/naloxone for chronic pain using a microdosing regimen: a case report. A A Pract. 2020;14(2):44\u20137.","journal-title":"A A Pract."},{"issue":"1","key":"2128_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00213-002-1003-8","volume":"161","author":"TM Tzschentke","year":"2002","unstructured":"Tzschentke TM. Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology. 2002;161(1):1\u201316.","journal-title":"Psychopharmacology"},{"issue":"5","key":"2128_CR45","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/phar.2676","volume":"42","author":"LA Spreen","year":"2022","unstructured":"Spreen LA, Dittmar EN, Quirk KC, Smith MA. Buprenorphine initiation strategies for opioid use disorder and pain management: a systematic review. Pharmacotherapy. 2022;42(5):411\u201327.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2128_CR46","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1089\/jpm.2021.0378","volume":"25","author":"K Quirk","year":"2022","unstructured":"Quirk K, Stevenson M. Buprenorphine microdosing for the pain and palliative care clinician. J Palliat Med. 2022;25(1):145\u201354.","journal-title":"J Palliat Med"},{"key":"2128_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.718811","volume":"12","author":"M Soyka","year":"2021","unstructured":"Soyka M. Transition from full mu opioid agonists to buprenorphine in opioid dependent patients-a critical review. Front Pharmacol. 2021;12: 718811.","journal-title":"Front Pharmacol"},{"issue":"7","key":"2128_CR48","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0196-0644(83)80343-6","volume":"12","author":"KA Handal","year":"1983","unstructured":"Handal KA, Schauben JL, Salamone FR. Naloxone. Ann Emerg Med. 1983;12(7):438\u201345.","journal-title":"Ann Emerg Med"},{"issue":"5","key":"2128_CR49","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S0196-0644(86)80994-5","volume":"15","author":"L Goldfrank","year":"1986","unstructured":"Goldfrank L, Weisman RS, Errick JK, Lo MW. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med. 1986;15(5):566\u201370.","journal-title":"Ann Emerg Med"},{"issue":"6","key":"2128_CR50","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/0030-4220(81)90077-3","volume":"52","author":"TJ Pallasch","year":"1981","unstructured":"Pallasch TJ, Gill CJ. Naloxone-associated morbidity and mortality. Oral Surg Oral Med Oral Pathol. 1981;52(6):602\u20133.","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"1","key":"2128_CR51","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1042\/BJ20111050","volume":"441","author":"P Huang","year":"2012","unstructured":"Huang P, Chen C, Mague SD, Blendy JA, Liu-Chen LY. A common single nucleotide polymorphism A118G of the mu opioid receptor alters its N-glycosylation and protein stability. Biochem J. 2012;441(1):379\u201386.","journal-title":"Biochem J"},{"key":"2128_CR52","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2147\/JPR.S42040","volume":"6","author":"E Mura","year":"2013","unstructured":"Mura E, Govoni S, Racchi M, Carossa V, Ranzani GN, Allegri M, et al. Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? J Pain Res. 2013;6:331\u201353.","journal-title":"J Pain Res"},{"issue":"2","key":"2128_CR53","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41397-020-00198-1","volume":"21","author":"CW Meaden","year":"2021","unstructured":"Meaden CW, Mozeika A, Asri R, Santos CD. A review of the existing literature on buprenorphine pharmacogenomics. Pharmacogenomics J. 2021;21(2):128\u201339.","journal-title":"Pharmacogenomics J"},{"issue":"13","key":"2128_CR54","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1073\/pnas.1523894113","volume":"113","author":"GF Marrone","year":"2016","unstructured":"Marrone GF, Grinnell SG, Lu Z, Rossi GC, Le Rouzic V, Xu J, et al. Truncated mu opioid GPCR variant involvement in opioid-dependent and opioid-independent pain modulatory systems within the CNS. Proc Natl Acad Sci USA. 2016;113(13):3663\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2128_CR55","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/syn.21914","volume":"70","author":"SG Grinnell","year":"2016","unstructured":"Grinnell SG, Ansonoff M, Marrone GF, Lu Z, Narayan A, Xu J, et al. Mediation of buprenorphine analgesia by a combination of traditional and truncated mu opioid receptor splice variants. Synapse. 2016;70(10):395\u2013407.","journal-title":"Synapse"},{"issue":"49","key":"2128_CR56","doi-asserted-by":"publisher","first-page":"19778","DOI":"10.1073\/pnas.1115231108","volume":"108","author":"S Majumdar","year":"2011","unstructured":"Majumdar S, Grinnell S, Le Rouzic V, Burgman M, Polikar L, Ansonoff M, et al. Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proc Natl Acad Sci USA. 2011;108(49):19778\u201383.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2128_CR57","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1021\/acsptsci.0c00066","volume":"3","author":"A Islam","year":"2020","unstructured":"Islam A, Rahman MA, Brenner MB, Moore A, Kellmyer A, Buechler HM, et al. Abuse liability, anti-nociceptive, and discriminative stimulus properties of IBNtxA. ACS Pharmacol Transl Sci. 2020;3(5):907\u201320.","journal-title":"ACS Pharmacol Transl Sci."},{"issue":"3","key":"2128_CR58","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0022-3565(24)35398-4","volume":"292","author":"PA Zaki","year":"2000","unstructured":"Zaki PA, Keith DE Jr, Brine GA, Carroll FI, Evans CJ. Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation? J Pharmacol Exp Ther. 2000;292(3):1127\u201334.","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"2128_CR59","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.clinthera.2005.06.024","volume":"27","author":"R Sittl","year":"2005","unstructured":"Sittl R, Nuijten M, Nautrup BP. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Clin Ther. 2005;27(7):1022\u201331.","journal-title":"Clin Ther"},{"issue":"2","key":"2128_CR60","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.clinthera.2005.02.012","volume":"27","author":"R Sittl","year":"2005","unstructured":"Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther. 2005;27(2):225\u201337.","journal-title":"Clin Ther"},{"issue":"4","key":"2128_CR61","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1124\/mol.120.119453","volume":"98","author":"T Zhang","year":"2020","unstructured":"Zhang T, Xu J, Pan YX. A Truncated six transmembrane splice variant MOR-1G enhances expression of the full-length seven transmembrane mu-opioid receptor through heterodimerization. Mol Pharmacol. 2020;98(4):518\u201327.","journal-title":"Mol Pharmacol"},{"key":"2128_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.110093","volume":"258","author":"S Singleton","year":"2024","unstructured":"Singleton S, Dieterle C, Walker DJ, Runeberg T, Oswald AS, Rosenqvist G, et al. Activation of mu receptors by SR-17018 through a distinctive mechanism. Neuropharmacology. 2024;258: 110093.","journal-title":"Neuropharmacology"},{"issue":"8","key":"2128_CR63","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1111\/bph.15409","volume":"178","author":"S Singleton","year":"2021","unstructured":"Singleton S, Baptista-Hon DT, Edelsten E, McCaughey KS, Camplisson E, Hales TG. TRV130 partial agonism and capacity to induce anti-nociceptive tolerance revealed through reducing available mu-opioid receptor number. Br J Pharmacol. 2021;178(8):1855\u201368.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"2128_CR64","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1111\/bph.12222","volume":"169","author":"E Kelly","year":"2013","unstructured":"Kelly E. Efficacy and ligand bias at the mu-opioid receptor. Br J Pharmacol. 2013;169(7):1430\u201346.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"2128_CR65","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1124\/pr.55.4.4","volume":"55","author":"RR Neubig","year":"2003","unstructured":"Neubig RR, Spedding M, Kenakin T, Christopoulos A, International Union of Pharmacology Committee on Receptor N, Drug C. International Union of Pharmacology Committee on receptor nomenclature and drug classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev. 2003;55(4):597\u2013606.","journal-title":"Pharmacol Rev"},{"issue":"3","key":"2128_CR66","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0014-2999(99)00460-4","volume":"378","author":"KO Lee","year":"1999","unstructured":"Lee KO, Akil H, Woods JH, Traynor JR. Differential binding properties of oripavines at cloned mu- and delta-opioid receptors. Eur J Pharmacol. 1999;378(3):323\u201330.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"2128_CR67","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0026-895X(25)08634-1","volume":"47","author":"JR Traynor","year":"1995","unstructured":"Traynor JR, Nahorski SR. Modulation by mu-opioid agonists of guanosine-5\u2019-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol. 1995;47(4):848\u201354.","journal-title":"Mol Pharmacol"},{"issue":"2","key":"2128_CR68","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S0022-3565(24)37462-2","volume":"285","author":"DE Selley","year":"1998","unstructured":"Selley DE, Liu Q, Childers SR. Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus. J Pharmacol Exp Ther. 1998;285(2):496\u2013505.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2128_CR69","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0022-3565(24)29586-0","volume":"297","author":"P Huang","year":"2001","unstructured":"Huang P, Kehner GB, Cowan A, Liu-Chen LY. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther. 2001;297(2):688\u201395.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2128_CR70","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0022-3565(25)24351-8","volume":"272","author":"K Raynor","year":"1995","unstructured":"Raynor K, Kong H, Mestek A, Bye LS, Tian M, Liu J, et al. Characterization of the cloned human mu opioid receptor. J Pharmacol Exp Ther. 1995;272(1):423\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2128_CR71","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1074\/jbc.272.2.782","volume":"272","author":"AD Blake","year":"1997","unstructured":"Blake AD, Bot G, Freeman JC, Reisine T. Differential opioid agonist regulation of the mouse mu opioid receptor. J Biol Chem. 1997;272(2):782\u201390.","journal-title":"J Biol Chem"},{"issue":"1","key":"2128_CR72","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0022-3565(24)35065-7","volume":"291","author":"P Sanchez-Blazquez","year":"1999","unstructured":"Sanchez-Blazquez P, Rodriguez-Diaz M, DeAntonio I, Garzon J. Endomorphin-1 and endomorphin-2 show differences in their activation of mu opioid receptor-regulated G proteins in supraspinal antinociception in mice. J Pharmacol Exp Ther. 1999;291(1):12\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2128_CR73","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0361-9230(00)00448-2","volume":"54","author":"P Sanchez-Blazquez","year":"2001","unstructured":"Sanchez-Blazquez P, Gomez-Serranillos P, Garzon J. Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. Brain Res Bull. 2001;54(2):229\u201335.","journal-title":"Brain Res Bull"},{"issue":"3","key":"2128_CR74","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0014-2999(91)90485-9","volume":"195","author":"H Wheeler-Aceto","year":"1991","unstructured":"Wheeler-Aceto H, Cowan A. Buprenorphine and morphine cause antinociception by different transduction mechanisms. Eur J Pharmacol. 1991;195(3):411\u20133.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"2128_CR75","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/sj.bjp.0706661","volume":"147","author":"Z Saidak","year":"2006","unstructured":"Saidak Z, Blake-Palmer K, Hay DL, Northup JK, Glass M. Differential activation of G-proteins by mu-opioid receptor agonists. Br J Pharmacol. 2006;147(6):671\u201380.","journal-title":"Br J Pharmacol"},{"issue":"12","key":"2128_CR76","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.jmb.2017.05.009","volume":"429","author":"KJ Sutcliffe","year":"2017","unstructured":"Sutcliffe KJ, Henderson G, Kelly E, Sessions RB. Drug binding poses relate structure with efficacy in the mu opioid receptor. J Mol Biol. 2017;429(12):1840\u201351.","journal-title":"J Mol Biol"},{"issue":"5","key":"2128_CR77","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jpainsymman.2007.01.006","volume":"34","author":"S Mercadante","year":"2007","unstructured":"Mercadante S, Porzio G, Fulfaro F, Aielli F, Verna L, Ficorella C, et al. Switching from transdermal drugs: an observational \u201cN of 1\u201d study of fentanyl and buprenorphine. J Pain Symptom Manag. 2007;34(5):532\u20138.","journal-title":"J Pain Symptom Manag"},{"key":"2128_CR78","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2147\/JPR.S36446","volume":"7","author":"TL Skaer","year":"2014","unstructured":"Skaer TL. Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain. J Pain Res. 2014;7:495\u2013503.","journal-title":"J Pain Res"},{"issue":"1","key":"2128_CR79","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1038\/s41467-019-11875-6","volume":"10","author":"B Benredjem","year":"2019","unstructured":"Benredjem B, Gallion J, Pelletier D, Dallaire P, Charbonneau J, Cawkill D, et al. Exploring use of unsupervised clustering to associate signaling profiles of GPCR ligands to clinical response. Nat Commun. 2019;10(1):4075.","journal-title":"Nat Commun"},{"issue":"1","key":"2128_CR80","doi-asserted-by":"publisher","first-page":"7885","DOI":"10.1038\/s41598-017-07392-5","volume":"7","author":"L Onfroy","year":"2017","unstructured":"Onfroy L, Galandrin S, Pontier SM, Seguelas MH, N\u2019Guyen D, Senard JM, et al. G protein stoichiometry dictates biased agonism through distinct receptor-G protein partitioning. Sci Rep. 2017;7(1):7885.","journal-title":"Sci Rep"},{"issue":"3","key":"2128_CR81","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/ALN.0000000000000984","volume":"124","author":"G Montandon","year":"2016","unstructured":"Montandon G, Ren J, Victoria NC, Liu H, Wickman K, Greer JJ, et al. G-protein-gated inwardly rectifying potassium channels modulate respiratory depression by opioids. Anesthesiology. 2016;124(3):641\u201350.","journal-title":"Anesthesiology"},{"issue":"7","key":"2128_CR82","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5055\/jom.2021.0639","volume":"17","author":"J Bettinger","year":"2021","unstructured":"Bettinger J, Batista Quevedo H, Cleary J. Emerging pharmacologic mechanisms of buprenorphine to explain experience of analgesia versus adverse effects. J Opioid Manag. 2021;17(7):21\u201331.","journal-title":"J Opioid Manag"},{"issue":"4","key":"2128_CR83","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41589-022-01208-y","volume":"19","author":"Q Qu","year":"2023","unstructured":"Qu Q, Huang W, Aydin D, Paggi JM, Seven AB, Wang H, et al. Insights into distinct signaling profiles of the microOR activated by diverse agonists. Nat Chem Biol. 2023;19(4):423\u201330.","journal-title":"Nat Chem Biol"},{"key":"2128_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fnsys.2022.937126","volume":"16","author":"S Adhikary","year":"2022","unstructured":"Adhikary S, Williams JT. Cellular tolerance induced by chronic opioids in the central nervous system. Front Syst Neurosci. 2022;16: 937126.","journal-title":"Front Syst Neurosci"},{"issue":"22","key":"2128_CR85","doi-asserted-by":"publisher","first-page":"7253","DOI":"10.1073\/pnas.81.22.7253","volume":"81","author":"C Chavkin","year":"1984","unstructured":"Chavkin C, Goldstein A. Opioid receptor reserve in normal and morphine-tolerant guinea pig ileum myenteric plexus. Proc Natl Acad Sci USA. 1984;81(22):7253\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"2128_CR86","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1111\/bph.15064","volume":"177","author":"DT Baptista-Hon","year":"2020","unstructured":"Baptista-Hon DT, Smith M, Singleton S, Antonides LH, Nic Daeid N, McKenzie C, et al. Activation of mu-opioid receptors by MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) and its fluorinated derivatives. Br J Pharmacol. 2020;177(15):3436\u201348.","journal-title":"Br J Pharmacol"},{"issue":"5\u20136","key":"2128_CR87","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1046\/j.1440-1681.2003.03835.x","volume":"30","author":"PH Tso","year":"2003","unstructured":"Tso PH, Wong YH. Molecular basis of opioid dependence: role of signal regulation by G-proteins. Clin Exp Pharmacol Physiol. 2003;30(5\u20136):307\u201316.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"405","key":"2128_CR88","doi-asserted-by":"publisher","first-page":"ra123","DOI":"10.1126\/scisignal.aab4068","volume":"8","author":"I Masuho","year":"2015","unstructured":"Masuho I, Ostrovskaya O, Kramer GM, Jones CD, Xie K, Martemyanov KA. Distinct profiles of functional discrimination among G proteins determine the actions of G protein-coupled receptors. Sci Signal. 2015;8(405):ra123.","journal-title":"Sci Signal."},{"issue":"1","key":"2128_CR89","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1046\/j.1471-4159.2003.02139.x","volume":"88","author":"I Masuho","year":"2004","unstructured":"Masuho I, Itoh M, Itoh H, Saitoh O. The mechanism of membrane-translocation of regulator of G-protein signaling (RGS) 8 induced by Galpha expression. J Neurochem. 2004;88(1):161\u20138.","journal-title":"J Neurochem"},{"issue":"5","key":"2128_CR90","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1124\/mol.107.043547","volume":"73","author":"MJ Clark","year":"2008","unstructured":"Clark MJ, Linderman JJ, Traynor JR. Endogenous regulators of G protein signaling differentially modulate full and partial mu-opioid agonists at adenylyl cyclase as predicted by a collision coupling model. Mol Pharmacol. 2008;73(5):1538\u201348.","journal-title":"Mol Pharmacol"},{"issue":"22","key":"2128_CR91","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.1523\/JNEUROSCI.3723-08.2009","volume":"29","author":"MS Virk","year":"2009","unstructured":"Virk MS, Arttamangkul S, Birdsong WT, Williams JT. Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009;29(22):7341\u20138.","journal-title":"J Neurosci"},{"issue":"4","key":"2128_CR92","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1124\/mol.110.066613","volume":"78","author":"J McPherson","year":"2010","unstructured":"McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, Krasel C, et al. mu-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol. 2010;78(4):756\u201366.","journal-title":"Mol Pharmacol"},{"issue":"3","key":"2128_CR93","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1124\/mol.112.082875","volume":"83","author":"S Just","year":"2013","unstructured":"Just S, Illing S, Trester-Zedlitz M, Lau EK, Kotowski SJ, Miess E, et al. Differentiation of opioid drug effects by hierarchical multi-site phosphorylation. Mol Pharmacol. 2013;83(3):633\u20139.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"2128_CR94","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1124\/mol.104.004994","volume":"67","author":"T Koch","year":"2005","unstructured":"Koch T, Widera A, Bartzsch K, Schulz S, Brandenburg LO, Wundrack N, et al. Receptor endocytosis counteracts the development of opioid tolerance. Mol Pharmacol. 2005;67(1):280\u20137.","journal-title":"Mol Pharmacol"},{"issue":"16","key":"2128_CR95","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/sj.emboj.7600334","volume":"23","author":"S Schulz","year":"2004","unstructured":"Schulz S, Mayer D, Pfeiffer M, Stumm R, Koch T, Hollt V. Morphine induces terminal micro-opioid receptor desensitization by sustained phosphorylation of serine-375. EMBO J. 2004;23(16):3282\u20139.","journal-title":"EMBO J"},{"issue":"32","key":"2128_CR96","doi-asserted-by":"publisher","first-page":"10331","DOI":"10.1523\/JNEUROSCI.23-32-10331.2003","volume":"23","author":"K Lutfy","year":"2003","unstructured":"Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, et al. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci. 2003;23(32):10331\u20137.","journal-title":"J Neurosci"},{"issue":"25","key":"2128_CR97","doi-asserted-by":"publisher","first-page":"11608","DOI":"10.1073\/pnas.1000751107","volume":"107","author":"EJ Melief","year":"2010","unstructured":"Melief EJ, Miyatake M, Bruchas MR, Chavkin C. Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci USA. 2010;107(25):11608\u201313.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"41","key":"2128_CR98","doi-asserted-by":"publisher","first-page":"29803","DOI":"10.1074\/jbc.M705540200","volume":"282","author":"MR Bruchas","year":"2007","unstructured":"Bruchas MR, Yang T, Schreiber S, Defino M, Kwan SC, Li S, et al. Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. J Biol Chem. 2007;282(41):29803\u201311.","journal-title":"J Biol Chem"},{"issue":"7","key":"2128_CR99","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/00008877-200211000-00005","volume":"13","author":"SS Negus","year":"2002","unstructured":"Negus SS, Bidlack JM, Mello NK, Furness MS, Rice KC, Brandt MR. Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behav Pharmacol. 2002;13(7):557\u201370.","journal-title":"Behav Pharmacol"},{"issue":"3","key":"2128_CR100","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/S0022-3565(25)13078-4","volume":"277","author":"MM Belcheva","year":"1996","unstructured":"Belcheva MM, Ho MT, Ignatova EG, Jefcoat LB, Barg J, Vogel Z, et al. Buprenorphine differentially alters opioid receptor adaptation in rat brain regions. J Pharmacol Exp Ther. 1996;277(3):1322\u20137.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2128_CR101","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/(SICI)1098-2396(199911)34:2<83::AID-SYN1>3.0.CO;2-S","volume":"34","author":"DV Romero","year":"1999","unstructured":"Romero DV, Partilla JS, Zheng QX, Heyliger SO, Ni Q, Rice KC, et al. Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu\/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay. Synapse. 1999;34(2):83\u201394.","journal-title":"Synapse"},{"issue":"6","key":"2128_CR102","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.tips.2006.04.005","volume":"27","author":"X Zhang","year":"2006","unstructured":"Zhang X, Bao L, Guan JS. Role of delivery and trafficking of delta-opioid peptide receptors in opioid analgesia and tolerance. Trends Pharmacol Sci. 2006;27(6):324\u20139.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"2128_CR103","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1124\/jpet.302.1.188","volume":"302","author":"GM Zhao","year":"2002","unstructured":"Zhao GM, Wu D, Soong Y, Shimoyama M, Berezowska I, Schiller PW, et al. Profound spinal tolerance after repeated exposure to a highly selective mu-opioid peptide agonist: role of delta-opioid receptors. J Pharmacol Exp Ther. 2002;302(1):188\u201396.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2128_CR104","first-page":"93","volume":"224","author":"JJ Rady","year":"2000","unstructured":"Rady JJ, Holmes BB, Portoghese PS, Fujimoto JM. Morphine tolerance in mice changes response of heroin from mu to delta opioid receptors. Proc Soc Exp Biol Med. 2000;224(2):93\u2013101.","journal-title":"Proc Soc Exp Biol Med"},{"issue":"1","key":"2128_CR105","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0022-3565(25)20227-0","volume":"258","author":"EE Abdelhamid","year":"1991","unstructured":"Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther. 1991;258(1):299\u2013303.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2128_CR106","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0022-3565(25)22685-4","volume":"240","author":"RD Russell","year":"1987","unstructured":"Russell RD, Leslie JB, Su YF, Watkins WD, Chang KJ. Continuous intrathecal opioid analgesia: tolerance and cross-tolerance of mu and delta spinal opioid receptors. J Pharmacol Exp Ther. 1987;240(1):150\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2128_CR107","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bph.12618","volume":"172","author":"P Klenowski","year":"2015","unstructured":"Klenowski P, Morgan M, Bartlett SE. The role of delta-opioid receptors in learning and memory underlying the development of addiction. Br J Pharmacol. 2015;172(2):297\u2013310.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"2128_CR108","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/ijnp\/pyad032","volume":"26","author":"A Requana Aradas","year":"2023","unstructured":"Requana Aradas A, Djaboub Y, McCort-Tranchepain I, Hajasova Z, Clemenceau L, Canestrelli C, et al. Activation of the mu-delta opioid receptor heteromers blocks morphine rewarding effects. Int J Neuropsychopharmacol. 2023;26(7):513\u201321.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"2128_CR109","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/ijnp\/pyaa069","volume":"24","author":"HR Kranzler","year":"2021","unstructured":"Kranzler HR, Lynch KG, Crist RC, Hartwell E, Le Moigne A, Laffont CM, et al. A delta-opioid receptor gene polymorphism moderates the therapeutic response to extended-release buprenorphine in opioid use disorder. Int J Neuropsychopharmacol. 2021;24(2):89\u201396.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"14","key":"2128_CR110","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.3390\/molecules29143331","volume":"29","author":"SS Negus","year":"2024","unstructured":"Negus SS, St Onge CM, Lee YK, Li M, Rice KC, Zhang Y. Effects of selective and mixed-action kappa and delta opioid receptor agonists on pain-related behavioral depression in mice. Molecules. 2024;29(14):3331.","journal-title":"Molecules"},{"issue":"6","key":"2128_CR111","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00213-015-4195-4","volume":"233","author":"EM Richards","year":"2016","unstructured":"Richards EM, Mathews DC, Luckenbaugh DA, Ionescu DF, Machado-Vieira R, Niciu MJ, et al. A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression. Psychopharmacology. 2016;233(6):1119\u201330.","journal-title":"Psychopharmacology"},{"issue":"2","key":"2128_CR112","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.neuropharm.2007.10.007","volume":"54","author":"SA Perrine","year":"2008","unstructured":"Perrine SA, Sheikh IS, Nwaneshiudu CA, Schroeder JA, Unterwald EM. Withdrawal from chronic administration of cocaine decreases delta opioid receptor signaling and increases anxiety- and depression-like behaviors in the rat. Neuropharmacology. 2008;54(2):355\u201364.","journal-title":"Neuropharmacology"},{"issue":"3","key":"2128_CR113","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1124\/jpet.105.095810","volume":"317","author":"EM Jutkiewicz","year":"2006","unstructured":"Jutkiewicz EM, Baladi MG, Folk JE, Rice KC, Woods JH. The convulsive and electroencephalographic changes produced by nonpeptidic delta-opioid agonists in rats: comparison with pentylenetetrazol. J Pharmacol Exp Ther. 2006;317(3):1337\u201348.","journal-title":"J Pharmacol Exp Ther"},{"issue":"131","key":"2128_CR114","doi-asserted-by":"publisher","first-page":"ra54","DOI":"10.1126\/scisignal.2000807","volume":"3","author":"A Gupta","year":"2010","unstructured":"Gupta A, Mulder J, Gomes I, Rozenfeld R, Bushlin I, Ong E, et al. Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal. 2010;3(131):ra54.","journal-title":"Sci Signal."},{"issue":"41","key":"2128_CR115","doi-asserted-by":"publisher","first-page":"16045","DOI":"10.1073\/pnas.0804106105","volume":"105","author":"FM Decaillot","year":"2008","unstructured":"Decaillot FM, Rozenfeld R, Gupta A, Devi LA. Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4. Proc Natl Acad Sci USA. 2008;105(41):16045\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"2128_CR116","doi-asserted-by":"publisher","first-page":"RC110","DOI":"10.1523\/JNEUROSCI.20-22-j0007.2000","volume":"20","author":"I Gomes","year":"2000","unstructured":"Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA. Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci. 2000;20(22):RC110.","journal-title":"J Neurosci"},{"issue":"3","key":"2128_CR117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058362","volume":"8","author":"L Milan-Lobo","year":"2013","unstructured":"Milan-Lobo L, Enquist J, van Rijn RM, Whistler JL. Anti-analgesic effect of the mu\/delta opioid receptor heteromer revealed by ligand-biased antagonism. PLoS ONE. 2013;8(3): e58362.","journal-title":"PLoS ONE"},{"key":"2128_CR118","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1100\/tsw.2007.219","volume":"7","author":"R Rozenfeld","year":"2007","unstructured":"Rozenfeld R, Abul-Husn NS, Gomez I, Devi LA. An emerging role for the delta opioid receptor in the regulation of mu opioid receptor function. Sci World J. 2007;7:64\u201373.","journal-title":"Sci World J"},{"key":"2128_CR119","doi-asserted-by":"publisher","first-page":"174480691876949","DOI":"10.1177\/1744806918769492","volume":"14","author":"F Bao","year":"2018","unstructured":"Bao F, Li CL, Chen XQ, Lu YJ, Bao L, Zhang X. Clinical opioids differentially induce co-internalization of mu- and delta-opioid receptors. Mol Pain. 2018;14:1744806918769492.","journal-title":"Mol Pain"},{"issue":"24","key":"2128_CR120","doi-asserted-by":"publisher","first-page":"10906","DOI":"10.1523\/JNEUROSCI.22-24-10906.2002","volume":"22","author":"JF Nitsche","year":"2002","unstructured":"Nitsche JF, Schuller AG, King MA, Zengh M, Pasternak GW, Pintar JE. Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice. J Neurosci. 2002;22(24):10906\u201313.","journal-title":"J Neurosci"},{"issue":"1","key":"2128_CR121","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/j.pain.0000000000002320","volume":"163","author":"A Keresztes","year":"2022","unstructured":"Keresztes A, Olson K, Nguyen P, Lopez-Pier MA, Hecksel R, Barker NK, et al. Antagonism of the mu-delta opioid receptor heterodimer enhances opioid antinociception by activating Src and calcium\/calmodulin-dependent protein kinase II signaling. Pain. 2022;163(1):146\u201358.","journal-title":"Pain"},{"issue":"52","key":"2128_CR122","doi-asserted-by":"publisher","first-page":"19208","DOI":"10.1073\/pnas.0506627102","volume":"102","author":"DJ Daniels","year":"2005","unstructured":"Daniels DJ, Lenard NR, Etienne CL, Law PY, Roerig SC, Portoghese PS. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci USA. 2005;102(52):19208\u201313.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1\u20133","key":"2128_CR123","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejphar.2007.02.040","volume":"566","author":"NR Lenard","year":"2007","unstructured":"Lenard NR, Daniels DJ, Portoghese PS, Roerig SC. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores. Eur J Pharmacol. 2007;566(1\u20133):75\u201382.","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"2128_CR124","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1021\/acs.jmedchem.5b00130","volume":"58","author":"JP Cueva","year":"2015","unstructured":"Cueva JP, Roche C, Ostovar M, Kumar V, Clark MJ, Hillhouse TM, et al. C7beta-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin\/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors. J Med Chem. 2015;58(10):4242\u20139.","journal-title":"J Med Chem"},{"issue":"8","key":"2128_CR125","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1021\/jm301543e","volume":"56","author":"BM Greedy","year":"2013","unstructured":"Greedy BM, Bradbury F, Thomas MP, Grivas K, Cami-Kobeci G, Archambeau A, et al. Orvinols with mixed kappa\/mu opioid receptor agonist activity. J Med Chem. 2013;56(8):3207\u201316.","journal-title":"J Med Chem"},{"issue":"4","key":"2128_CR126","doi-asserted-by":"publisher","first-page":"e01111","DOI":"10.1002\/prp2.1111","volume":"11","author":"EJ Santos","year":"2023","unstructured":"Santos EJ, Nassehi N, Bow EW, Chambers DR, Gutman ES, Jacobson AE, et al. Role of efficacy as a determinant of locomotor activation by mu-opioid receptor (MOR) ligands in female and male mice. II. Effects of novel MOR-selective phenylmorphans with high-to-low MOR efficacy. Pharmacol Res Perspect. 2023;11(4):e01111.","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"2128_CR127","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S0022-3565(25)20058-1","volume":"232","author":"TP Su","year":"1985","unstructured":"Su TP. Further demonstration of kappa opioid binding sites in the brain: evidence for heterogeneity. J Pharmacol Exp Ther. 1985;232(1):144\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2128_CR128","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0022-3565(25)21772-4","volume":"229","author":"AM Young","year":"1984","unstructured":"Young AM, Stephens KR, Hein DW, Woods JH. Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids. J Pharmacol Exp Ther. 1984;229(1):118\u201326.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2128_CR129","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S0022-3565(24)36877-6","volume":"282","author":"J Zhu","year":"1997","unstructured":"Zhu J, Luo LY, Li JG, Chen C, Liu-Chen LY. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. J Pharmacol Exp Ther. 1997;282(2):676\u201384.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2128_CR130","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0006-8993(96)01069-4","volume":"744","author":"CG Pick","year":"1997","unstructured":"Pick CG, Peter Y, Schreiber S, Weizman R. Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia. Brain Res. 1997;744(1):41\u20136.","journal-title":"Brain Res"},{"issue":"4","key":"2128_CR131","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/sj.bjp.0706601","volume":"147","author":"MC Olianas","year":"2006","unstructured":"Olianas MC, Concas D, Onali P. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors. Br J Pharmacol. 2006;147(4):360\u201370.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2128_CR132","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.neuropharm.2004.09.016","volume":"48","author":"V Cox","year":"2005","unstructured":"Cox V, Clarke S, Czyzyk T, Ansonoff M, Nitsche J, Hsu MS, et al. Autoradiography in opioid triple knockout mice reveals opioid and opioid receptor like binding of naloxone benzoylhydrazone. Neuropharmacology. 2005;48(2):228\u201335.","journal-title":"Neuropharmacology"},{"issue":"3","key":"2128_CR133","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0006-291X(02)02258-1","volume":"297","author":"YX Pan","year":"2002","unstructured":"Pan YX, Bolan E, Pasternak GW. Dimerization of morphine and orphanin FQ\/nociceptin receptors: generation of a novel opioid receptor subtype. Biochem Biophys Res Commun. 2002;297(3):659\u201363.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2128_CR134","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1023\/A:1016340106299","volume":"2","author":"ML Richards","year":"1985","unstructured":"Richards ML, Sadee W. Buprenorphine is an antagonist at the varkappa opioid receptor. Pharm Res. 1985;2(4):178\u201381.","journal-title":"Pharm Res"},{"issue":"9","key":"2128_CR135","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/0028-3908(87)90112-2","volume":"26","author":"JD Leander","year":"1987","unstructured":"Leander JD. Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology. 1987;26(9):1445\u20137.","journal-title":"Neuropharmacology"},{"key":"2128_CR136","first-page":"518","volume":"95","author":"SS Negus","year":"1989","unstructured":"Negus SS, Picker MJ, Dykstra LA. Kappa antagonist effects of buprenorphine in the rat drug-discrimination procedure. NIDA Res Monogr. 1989;95:518\u20139.","journal-title":"NIDA Res Monogr"},{"issue":"1","key":"2128_CR137","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/BF00442021","volume":"98","author":"SS Negus","year":"1989","unstructured":"Negus SS, Picker MJ, Dykstra LA. Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats. Psychopharmacology. 1989;98(1):141\u20133.","journal-title":"Psychopharmacology"},{"key":"2128_CR138","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.brainres.2009.08.062","volume":"1314","author":"MR Bruchas","year":"2010","unstructured":"Bruchas MR, Land BB, Chavkin C. The dynorphin\/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. 2010;1314:44\u201355.","journal-title":"Brain Res"},{"key":"2128_CR139","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.brainres.2009.09.074","volume":"1314","author":"AT Knoll","year":"2010","unstructured":"Knoll AT, Carlezon WA Jr. Dynorphin, stress, and depression. Brain Res. 2010;1314:56\u201373.","journal-title":"Brain Res"},{"issue":"49","key":"2128_CR140","doi-asserted-by":"publisher","first-page":"19384","DOI":"10.1523\/JNEUROSCI.1979-13.2013","volume":"33","author":"JE Schlosburg","year":"2013","unstructured":"Schlosburg JE, Whitfield TW Jr, Park PE, Crawford EF, George O, Vendruscolo LF, et al. Long-term antagonism of kappa opioid receptors prevents escalation of and increased motivation for heroin intake. J Neurosci. 2013;33(49):19384\u201392.","journal-title":"J Neurosci"},{"issue":"4","key":"2128_CR141","first-page":"18","volume":"32","author":"M Fava","year":"2020","unstructured":"Fava M, Mazzone E, Freeman M, Flynn M, Judge H, Hoeppner B, et al. Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2020;32(4):18\u201326.","journal-title":"Ann Clin Psychiatry"},{"key":"2128_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2023.114789","volume":"459","author":"F Fiatcoski","year":"2024","unstructured":"Fiatcoski F, Jesus CHA, de Melo TJ, Chichorro JG, Kopruszinski CM. Sex differences in descending control of nociception (DCN) responses after chronic orofacial pain induction in rats and the contribution of kappa opioid receptors. Behav Brain Res. 2024;459: 114789.","journal-title":"Behav Brain Res"},{"issue":"13","key":"2128_CR143","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1038\/s41386-018-0225-3","volume":"43","author":"RJ Valentino","year":"2018","unstructured":"Valentino RJ, Volkow ND. Untangling the complexity of opioid receptor function. Neuropsychopharmacology. 2018;43(13):2514\u201320.","journal-title":"Neuropsychopharmacology"},{"issue":"21","key":"2128_CR144","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1523\/JNEUROSCI.0274-19.2019","volume":"39","author":"SS Liu","year":"2019","unstructured":"Liu SS, Pickens S, Burma NE, Ibarra-Lecue I, Yang H, Xue L, et al. Kappa opioid receptors drive a tonic aversive component of chronic pain. J Neurosci. 2019;39(21):4162\u201378.","journal-title":"J Neurosci"},{"issue":"4","key":"2128_CR145","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/npp.2015.226","volume":"41","author":"EH Chartoff","year":"2016","unstructured":"Chartoff EH, Ebner SR, Sparrow A, Potter D, Baker PM, Ragozzino ME, et al. Relative timing between kappa opioid receptor activation and cocaine determines the impact on reward and dopamine release. Neuropsychopharmacology. 2016;41(4):989\u20131002.","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl 10","key":"2128_CR146","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1097\/AJP.0b013e3181c49e3a","volume":"26","author":"TW Vanderah","year":"2010","unstructured":"Vanderah TW. Delta and kappa opioid receptors as suitable drug targets for pain. Clin J Pain. 2010;26(Suppl 10):S10\u20135.","journal-title":"Clin J Pain"},{"issue":"4","key":"2128_CR147","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/j.pain.0000000000001458","volume":"160","author":"E Navratilova","year":"2019","unstructured":"Navratilova E, Ji G, Phelps C, Qu C, Hein M, Yakhnitsa V, et al. Kappa opioid signaling in the central nucleus of the amygdala promotes disinhibition and aversiveness of chronic neuropathic pain. Pain. 2019;160(4):824\u201332.","journal-title":"Pain"},{"issue":"1","key":"2128_CR148","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0006-8993(95)00279-Y","volume":"683","author":"I Nylander","year":"1995","unstructured":"Nylander I, Vlaskovska M, Terenius L. Brain dynorphin and enkephalin systems in Fischer and Lewis rats: effects of morphine tolerance and withdrawal. Brain Res. 1995;683(1):25\u201335.","journal-title":"Brain Res"},{"issue":"4","key":"2128_CR149","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/BF02245939","volume":"118","author":"I Nylander","year":"1995","unstructured":"Nylander I, Vlaskovska M, Terenius L. The effects of morphine treatment and morphine withdrawal on the dynorphin and enkephalin systems in Sprague-Dawley rats. Psychopharmacology. 1995;118(4):391\u2013400.","journal-title":"Psychopharmacology"},{"issue":"4765","key":"2128_CR150","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1126\/science.3016896","volume":"233","author":"A Pfeiffer","year":"1986","unstructured":"Pfeiffer A, Brantl V, Herz A, Emrich HM. Psychotomimesis mediated by kappa opiate receptors. Science. 1986;233(4765):774\u20136.","journal-title":"Science"},{"key":"2128_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynstr.2021.100325","volume":"14","author":"RCN Marchette","year":"2021","unstructured":"Marchette RCN, Gregory-Flores A, Tunstall BJ, Carlson ER, Jackson SN, Sulima A, et al. kappa-Opioid receptor antagonism reverses heroin withdrawal-induced hyperalgesia in male and female rats. Neurobiol Stress. 2021;14: 100325.","journal-title":"Neurobiol Stress."},{"issue":"1","key":"2128_CR152","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/npp.2015.258","volume":"41","author":"C Chavkin","year":"2016","unstructured":"Chavkin C, Koob GF. Dynorphin, dysphoria, and dependence: the stress of addiction. Neuropsychopharmacology. 2016;41(1):373\u20134.","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"2128_CR153","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1523\/JNEUROSCI.1978-13.2015","volume":"35","author":"TW Whitfield Jr","year":"2015","unstructured":"Whitfield TW Jr, Schlosburg JE, Wee S, Gould A, George O, Grant Y, et al. kappa Opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake. J Neurosci. 2015;35(10):4296\u2013305.","journal-title":"J Neurosci"},{"issue":"2","key":"2128_CR154","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00213-010-1825-8","volume":"210","author":"S Wee","year":"2010","unstructured":"Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology. 2010;210(2):121\u201335.","journal-title":"Psychopharmacology"},{"issue":"3","key":"2128_CR155","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/sj.npp.1301438","volume":"33","author":"BM Walker","year":"2008","unstructured":"Walker BM, Koob GF. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology. 2008;33(3):643\u201352.","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"2128_CR156","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3390\/cells13080705","volume":"13","author":"G Ji","year":"2024","unstructured":"Ji G, Presto P, Kiritoshi T, Chen Y, Navratilova E, Porreca F, et al. Chemogenetic manipulation of amygdala kappa opioid receptor neurons modulates amygdala neuronal activity and neuropathic pain behaviors. Cells. 2024;13(8):705.","journal-title":"Cells"},{"issue":"2","key":"2128_CR157","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/ALN.0000000000004773","volume":"140","author":"E Navratilova","year":"2024","unstructured":"Navratilova E, Qu C, Ji G, Neugebauer V, Guerrero M, Rosen H, et al. Opposing effects on descending control of nociception by micro and kappa opioid receptors in the anterior cingulate cortex. Anesthesiology. 2024;140(2):272\u201383.","journal-title":"Anesthesiology"},{"issue":"3","key":"2128_CR158","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/brain\/awac153","volume":"146","author":"H Ito","year":"2023","unstructured":"Ito H, Navratilova E, Vagnerova B, Watanabe M, Kopruszinski C, Moreira de Souza LH, et al. Chronic pain recruits hypothalamic dynorphin\/kappa opioid receptor signalling to promote wakefulness and vigilance. Brain. 2023;146(3):1186\u201399.","journal-title":"Brain"},{"issue":"43","key":"2128_CR159","doi-asserted-by":"publisher","first-page":"11614","DOI":"10.1523\/JNEUROSCI.3769-07.2007","volume":"27","author":"MR Bruchas","year":"2007","unstructured":"Bruchas MR, Land BB, Aita M, Xu M, Barot SK, Li S, et al. Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria. J Neurosci. 2007;27(43):11614\u201323.","journal-title":"J Neurosci"},{"issue":"9","key":"2128_CR160","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.1038\/s41380-020-0811-8","volume":"26","author":"B de Laat","year":"2021","unstructured":"de Laat B, Nabulsi N, Huang Y, O\u2019Malley SS, Froehlich JC, Morris ED, et al. Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving. Mol Psychiatry. 2021;26(9):5053\u201360.","journal-title":"Mol Psychiatry"},{"issue":"11","key":"2128_CR161","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.biopsych.2019.05.021","volume":"86","author":"B de Laat","year":"2019","unstructured":"de Laat B, Goldberg A, Shi J, Tetrault JM, Nabulsi N, Zheng MQ, et al. The kappa opioid receptor is associated with naltrexone-induced reduction of drinking and craving. Biol Psychiatry. 2019;86(11):864\u201371.","journal-title":"Biol Psychiatry"},{"key":"2128_CR162","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/7854_2021_288","volume":"58","author":"GF Koob","year":"2022","unstructured":"Koob GF. Anhedonia, hyperkatifeia, and negative reinforcement in substance use disorders. Curr Top Behav Neurosci. 2022;58:147\u201365.","journal-title":"Curr Top Behav Neurosci"},{"issue":"7","key":"2128_CR163","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/j.1526-4637.2010.00881.x","volume":"11","author":"J Shurman","year":"2010","unstructured":"Shurman J, Koob GF, Gutstein HB. Opioids, pain, the brain, and hyperkatifeia: a framework for the rational use of opioids for pain. Pain Med. 2010;11(7):1092\u20138.","journal-title":"Pain Med"},{"key":"2128_CR164","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3389\/fpsyt.2019.00592","volume":"10","author":"J Kakko","year":"2019","unstructured":"Kakko J, Alho H, Baldacchino A, Molina R, Nava FA, Shaya G. Craving in opioid use disorder: from neurobiology to clinical practice. Front Psychiatry. 2019;10:592.","journal-title":"Front Psychiatry."},{"key":"2128_CR165","doi-asserted-by":"publisher","first-page":"10009","DOI":"10.3389\/adar.2021.10009","volume":"1","author":"CM Cameron","year":"2021","unstructured":"Cameron CM, Nieto S, Bosler L, Wong M, Bishop I, Mooney L, et al. Mechanisms underlying the anti-suicidal treatment potential of buprenorphine. Adv Drug Alcohol Res. 2021;1:10009.","journal-title":"Adv Drug Alcohol Res."},{"issue":"6","key":"2128_CR166","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/acer.15078","volume":"47","author":"BE Pirino","year":"2023","unstructured":"Pirino BE, Kelley AM, Karkhanis AN, Barson JR. A critical review of effects on ethanol intake of the dynorphin\/kappa opioid receptor system in the extended amygdala: from inhibition to stimulation. Alcohol Clin Exp Res (Hoboken). 2023;47(6):1027\u201338.","journal-title":"Alcohol Clin Exp Res (Hoboken)."},{"issue":"1","key":"2128_CR167","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1038\/s41598-024-56500-9","volume":"14","author":"FJ Flores-Ramirez","year":"2024","unstructured":"Flores-Ramirez FJ, Illenberger JM, Pascasio G, Terenius L, Martin-Fardon R. LY2444296, a kappa-opioid receptor antagonist, selectively reduces alcohol drinking in male and female Wistar rats with a history of alcohol dependence. Sci Rep. 2024;14(1):5804.","journal-title":"Sci Rep"},{"issue":"8","key":"2128_CR168","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/j.pnpbp.2008.08.019","volume":"32","author":"F Nava","year":"2008","unstructured":"Nava F, Manzato E, Leonardi C, Lucchini A. Opioid maintenance therapy suppresses alcohol intake in heroin addicts with alcohol dependence: preliminary results of an open randomized study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1867\u201372.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2128_CR169","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jpsychires.2023.03.037","volume":"161","author":"NB Riblet","year":"2023","unstructured":"Riblet NB, Young-Xu Y, Shiner B, Schnurr PP, Watts BV. The efficacy and safety of buprenorphine for the treatment of depression: a systematic review and meta-analysis. J Psychiatr Res. 2023;161:393\u2013401.","journal-title":"J Psychiatr Res"},{"key":"2128_CR170","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1177\/00912174231225087","volume":"59","author":"J Ahmadi","year":"2023","unstructured":"Ahmadi J, Mansoori A, Mosavat SH, Bazrafshan A. Comparison of ketamine with buprenorphine as adjunctive therapy in the treatment of comorbid major depressive disorder and opium use disorders: a randomized controlled trial. Int J Psychiatry Med. 2023;59:521\u201335.","journal-title":"Int J Psychiatry Med"},{"issue":"10","key":"2128_CR171","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.biopsych.2013.03.014","volume":"75","author":"JL Kissler","year":"2014","unstructured":"Kissler JL, Sirohi S, Reis DJ, Jansen HT, Quock RM, Smith DG, et al. The one-two punch of alcoholism: role of central amygdala dynorphins\/kappa-opioid receptors. Biol Psychiatry. 2014;75(10):774\u201382.","journal-title":"Biol Psychiatry"},{"key":"2128_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2019.104504","volume":"129","author":"EB Margolis","year":"2019","unstructured":"Margolis EB, Karkhanis AN. Dopaminergic cellular and circuit contributions to kappa opioid receptor mediated aversion. Neurochem Int. 2019;129: 104504.","journal-title":"Neurochem Int"},{"issue":"9","key":"2128_CR173","doi-asserted-by":"publisher","DOI":"10.1002\/syn.22042","volume":"72","author":"JM Miller","year":"2018","unstructured":"Miller JM, Zanderigo F, Purushothaman PD, DeLorenzo C, Rubin-Falcone H, Ogden RT, et al. Kappa opioid receptor binding in major depression: a pilot study. Synapse. 2018;72(9): e22042.","journal-title":"Synapse"},{"key":"2128_CR174","doi-asserted-by":"publisher","first-page":"33401","DOI":"10.1038\/srep33401","volume":"6","author":"S Dogra","year":"2016","unstructured":"Dogra S, Kumar A, Umrao D, Sahasrabuddhe AA, Yadav PN. Chronic Kappa opioid receptor activation modulates NR2B: implication in treatment resistant depression. Sci Rep. 2016;6:33401.","journal-title":"Sci Rep"},{"issue":"9","key":"2128_CR175","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00702-002-0764-x","volume":"109","author":"M Ukai","year":"2002","unstructured":"Ukai M, Suzuki M, Mamiya T. Effects of U-50,488H, a kappa-opioid receptor agonist, on the learned helplessness model of depression in mice. J Neural Transm (Vienna). 2002;109(9):1221\u20135.","journal-title":"J Neural Transm (Vienna)"},{"key":"2128_CR176","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3389\/fpsyt.2014.00170","volume":"5","author":"L Lalanne","year":"2014","unstructured":"Lalanne L, Ayranci G, Kieffer BL, Lutz PE. The kappa opioid receptor: from addiction to depression, and back. Front Psychiatry. 2014;5:170.","journal-title":"Front Psychiatry."},{"issue":"7","key":"2128_CR177","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.biopsych.2013.04.028","volume":"74","author":"M Kallupi","year":"2013","unstructured":"Kallupi M, Wee S, Edwards S, Whitfield TW Jr, Oleata CS, Luu G, et al. Kappa opioid receptor-mediated dysregulation of gamma-aminobutyric acidergic transmission in the central amygdala in cocaine addiction. Biol Psychiatry. 2013;74(7):520\u20138.","journal-title":"Biol Psychiatry"},{"issue":"9","key":"2128_CR178","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/aps.2010.138","volume":"31","author":"YH Wang","year":"2010","unstructured":"Wang YH, Sun JF, Tao YM, Chi ZQ, Liu JG. The role of kappa-opioid receptor activation in mediating antinociception and addiction. Acta Pharmacol Sin. 2010;31(9):1065\u201370.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"2128_CR179","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/npp.2008.165","volume":"34","author":"TS Shippenberg","year":"2009","unstructured":"Shippenberg TS. The dynorphin\/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders? Neuropsychopharmacology. 2009;34(1):247.","journal-title":"Neuropsychopharmacology"},{"key":"2128_CR180","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jad.2020.09.036","volume":"278","author":"P van der Venne","year":"2021","unstructured":"van der Venne P, Balint A, Drews E, Parzer P, Resch F, Koenig J, et al. Pain sensitivity and plasma beta-endorphin in adolescent non-suicidal self-injury. J Affect Disord. 2021;278:199\u2013208.","journal-title":"J Affect Disord"},{"issue":"2","key":"2128_CR181","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/13811118.2022.2066494","volume":"27","author":"N Cakin Memik","year":"2023","unstructured":"Cakin Memik N, Hunc F, Kalayci S, Demir N, Senturk E, Yildiz Gundogdu O, et al. Assessment of plasma-endogenous opioid neuropeptide levels and psychometric properties of non-suicidal self-injury in adolescents. Arch Suicide Res. 2023;27(2):749\u201368.","journal-title":"Arch Suicide Res"},{"issue":"6","key":"2128_CR182","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11916-022-01043-9","volume":"26","author":"BN Johnson","year":"2022","unstructured":"Johnson BN, McKernan LC, Bruehl S. A theoretical endogenous opioid neurobiological framework for co-occurring pain, trauma, and non-suicidal self-injury. Curr Pain Headache Rep. 2022;26(6):405\u201314.","journal-title":"Curr Pain Headache Rep"},{"issue":"3","key":"2128_CR183","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1515\/ijamh-2013-0069","volume":"25","author":"LJ Norelli","year":"2013","unstructured":"Norelli LJ, Smith HS, Sher L, Blackwood TA. Buprenorphine in the treatment of non-suicidal self-injury: a case series and discussion of the literature. Int J Adolesc Med Health. 2013;25(3):323\u201330.","journal-title":"Int J Adolesc Med Health"},{"issue":"3","key":"2128_CR184","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/sj.bjp.0707598","volume":"153","author":"B Spagnolo","year":"2008","unstructured":"Spagnolo B, Calo G, Polgar WE, Jiang F, Olsen CM, Berzetei-Gurske I, et al. Activities of mixed NOP and mu-opioid receptor ligands. Br J Pharmacol. 2008;153(3):609\u201319.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2128_CR185","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0014-2999(01)01282-1","volume":"428","author":"N Zaveri","year":"2001","unstructured":"Zaveri N, Polgar WE, Olsen CM, Kelson AB, Grundt P, Lewis JW, et al. Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors. Eur J Pharmacol. 2001;428(1):29\u201336.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2128_CR186","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S0026-895X(24)12643-0","volume":"56","author":"S Wnendt","year":"1999","unstructured":"Wnendt S, Kruger T, Janocha E, Hildebrandt D, Englberger W. Agonistic effect of buprenorphine in a nociceptin\/OFQ receptor-triggered reporter gene assay. Mol Pharmacol. 1999;56(2):334\u20138.","journal-title":"Mol Pharmacol"},{"issue":"5","key":"2128_CR187","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0143-4179(97)90032-9","volume":"31","author":"ID Adapa","year":"1997","unstructured":"Adapa ID, Toll L. Relationship between binding affinity and functional activity of nociceptin\/orphanin FQ. Neuropeptides. 1997;31(5):403\u20138.","journal-title":"Neuropeptides"},{"issue":"7","key":"2128_CR188","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0196-9781(00)00252-7","volume":"21","author":"P Bloms-Funke","year":"2000","unstructured":"Bloms-Funke P, Gillen C, Schuettler AJ, Wnendt S. Agonistic effects of the opioid buprenorphine on the nociceptin\/OFQ receptor. Peptides. 2000;21(7):1141\u20136.","journal-title":"Peptides"},{"key":"2128_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106283","volume":"178","author":"H Hakomaki","year":"2022","unstructured":"Hakomaki H, Eskola S, Kokki H, Lehtonen M, Rasanen J, Laaksonen S, et al. Central nervous system distribution of buprenorphine in pregnant sheep, fetuses and newborn lambs after continuous transdermal and single subcutaneous extended-release dosing. Eur J Pharm Sci. 2022;178: 106283.","journal-title":"Eur J Pharm Sci"},{"key":"2128_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105936","volume":"165","author":"H Hakomaki","year":"2021","unstructured":"Hakomaki H, Kokki H, Lehtonen M, Rasanen J, Voipio HM, Ranta VP, et al. Maternal and fetal buprenorphine pharmacokinetics in pregnant sheep during transdermal patch dosing: Buprenorphine pharmacokinetics in pregnant sheep. Eur J Pharm Sci. 2021;165: 105936.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"2128_CR191","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.726","volume":"9","author":"H Hakomaki","year":"2021","unstructured":"Hakomaki H, Kokki H, Lehtonen M, Ranta VP, Rasanen J, Voipio HM, et al. Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection. Pharmacol Res Perspect. 2021;9(2): e00726.","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"2128_CR192","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/00498250701251126","volume":"37","author":"ML Jensen","year":"2007","unstructured":"Jensen ML, Foster D, Upton R, Grant C, Martinez A, Somogyi A. Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. Xenobiotica. 2007;37(4):441\u201357.","journal-title":"Xenobiotica"},{"issue":"5","key":"2128_CR193","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1476-5381.2009.00209.x","volume":"157","author":"Z Ding","year":"2009","unstructured":"Ding Z, Raffa RB. Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br J Pharmacol. 2009;157(5):831\u201343.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2128_CR194","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1124\/jpet.106.111997","volume":"320","author":"TV Khroyan","year":"2007","unstructured":"Khroyan TV, Zaveri NT, Polgar WE, Orduna J, Olsen C, Jiang F, et al. SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin\/orphanin FQ\/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice. J Pharmacol Exp Ther. 2007;320(2):934\u201343.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2128_CR195","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/jnr.24624","volume":"100","author":"N Kiguchi","year":"2022","unstructured":"Kiguchi N, Ding H, Ko MC. Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse. J Neurosci Res. 2022;100(1):191\u2013202.","journal-title":"J Neurosci Res"},{"issue":"1","key":"2128_CR196","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0306-4522(96)00322-3","volume":"75","author":"NP Murphy","year":"1996","unstructured":"Murphy NP, Ly HT, Maidment NT. Intracerebroventricular orphanin FQ\/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats. Neuroscience. 1996;75(1):1\u20134.","journal-title":"Neuroscience"},{"issue":"1","key":"2128_CR197","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1046\/j.1471-4159.1999.0730179.x","volume":"73","author":"NP Murphy","year":"1999","unstructured":"Murphy NP, Maidment NT. Orphanin FQ\/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis. J Neurochem. 1999;73(1):179\u201386.","journal-title":"J Neurochem"},{"key":"2128_CR198","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.983595","volume":"13","author":"F Wang","year":"2022","unstructured":"Wang F, Shen W, Cai Y, Zhang X, Du H, Lai M, et al. Buprenorphine reduces methamphetamine intake and drug seeking behavior via activating nociceptin\/orphanin FQ peptide receptor in rats. Front Psychiatry. 2022;13: 983595.","journal-title":"Front Psychiatry."},{"issue":"1","key":"2128_CR199","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.biopsych.2006.01.006","volume":"61","author":"R Ciccocioppo","year":"2007","unstructured":"Ciccocioppo R, Economidou D, Rimondini R, Sommer W, Massi M, Heilig M. Buprenorphine reduces alcohol drinking through activation of the nociceptin\/orphanin FQ-NOP receptor system. Biol Psychiatry. 2007;61(1):4\u201312.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"2128_CR200","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.neuroscience.2008.06.027","volume":"155","author":"P Marquez","year":"2008","unstructured":"Marquez P, Borse J, Nguyen AT, Hamid A, Lutfy K. The role of the opioid receptor-like (ORL1) receptor in motor stimulatory and rewarding actions of buprenorphine and morphine. Neuroscience. 2008;155(3):597\u2013602.","journal-title":"Neuroscience"},{"issue":"1","key":"2128_CR201","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.pain.2009.10.026","volume":"148","author":"E Hu","year":"2010","unstructured":"Hu E, Calo G, Guerrini R, Ko MC. Long-lasting antinociceptive spinal effects in primates of the novel nociceptin\/orphanin FQ receptor agonist UFP-112. Pain. 2010;148(1):107\u201313.","journal-title":"Pain"},{"issue":"2","key":"2128_CR202","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1021\/cn300124f","volume":"4","author":"AP Lin","year":"2013","unstructured":"Lin AP, Ko MC. The therapeutic potential of nociceptin\/orphanin FQ receptor agonists as analgesics without abuse liability. ACS Chem Neurosci. 2013;4(2):214\u201324.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"2128_CR203","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1124\/jpet.112.194308","volume":"343","author":"CM Cremeans","year":"2012","unstructured":"Cremeans CM, Gruley E, Kyle DJ, Ko MC. Roles of mu-opioid receptors and nociceptin\/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates. J Pharmacol Exp Ther. 2012;343(1):72\u201381.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2128_CR204","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1254\/jphs.13029SC","volume":"122","author":"T Takahashi","year":"2013","unstructured":"Takahashi T, Okubo K, Kojima S, Nishikawa H, Takemura M, Tsubota-Matsunami M, et al. Antihyperalgesic effect of buprenorphine involves nociceptin\/orphanin FQ peptide-receptor activation in rats with spinal nerve injury-induced neuropathy. J Pharmacol Sci. 2013;122(1):51\u20134.","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"2128_CR205","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1124\/jpet.105.100859","volume":"318","author":"T Yamamoto","year":"2006","unstructured":"Yamamoto T, Shono K, Tanabe S. Buprenorphine activates mu and opioid receptor like-1 receptors simultaneously, but the analgesic effect is mainly mediated by mu receptor activation in the rat formalin test. J Pharmacol Exp Ther. 2006;318(1):206\u201313.","journal-title":"J Pharmacol Exp Ther"},{"issue":"37","key":"2128_CR206","doi-asserted-by":"publisher","first-page":"E5511","DOI":"10.1073\/pnas.1605295113","volume":"113","author":"H Ding","year":"2016","unstructured":"Ding H, Czoty PW, Kiguchi N, Cami-Kobeci G, Sukhtankar DD, Nader MA, et al. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Proc Natl Acad Sci USA. 2016;113(37):E5511\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"456","key":"2128_CR207","doi-asserted-by":"publisher","first-page":"eaar3483","DOI":"10.1126\/scitranslmed.aar3483","volume":"10","author":"H Ding","year":"2018","unstructured":"Ding H, Kiguchi N, Yasuda D, Daga PR, Polgar WE, Lu JJ, et al. A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates. Sci Transl Med. 2018;10(456):eaar3483.","journal-title":"Sci Transl Med."},{"issue":"6","key":"2128_CR208","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/j.bja.2018.10.065","volume":"122","author":"N Kiguchi","year":"2019","unstructured":"Kiguchi N, Ding H, Cami-Kobeci G, Sukhtankar DD, Czoty PW, DeLoid HB, et al. BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates. Br J Anaesth. 2019;122(6):e146\u201356.","journal-title":"Br J Anaesth"},{"key":"2128_CR209","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/164_2019_211","volume":"254","author":"N Kiguchi","year":"2019","unstructured":"Kiguchi N, Ko MC. Effects of NOP-related ligands in nonhuman primates. Handb Exp Pharmacol. 2019;254:323\u201343.","journal-title":"Handb Exp Pharmacol"},{"key":"2128_CR210","first-page":"136","volume":"49","author":"CP France","year":"1984","unstructured":"France CP, Jacobson AE, Woods JH. Irreversible and reversible narcotic agonists: discriminative and analgesic effects of buprenorphine, oxymorphazone, and morphine. NIDA Res Monogr. 1984;49:136\u201342.","journal-title":"NIDA Res Monogr"},{"issue":"5","key":"2128_CR211","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40261-021-01032-7","volume":"41","author":"JP De Aquino","year":"2021","unstructured":"De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. Clin Drug Investig. 2021;41(5):425\u201336.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"2128_CR212","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1124\/mol.112.079350","volume":"82","author":"VC Dang","year":"2012","unstructured":"Dang VC, Chieng BC, Christie MJ. Prolonged stimulation of mu-opioid receptors produces beta-arrestin-2-mediated heterologous desensitization of alpha(2)-adrenoceptor function in locus ceruleus neurons. Mol Pharmacol. 2012;82(3):473\u201380.","journal-title":"Mol Pharmacol"},{"issue":"3","key":"2128_CR213","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","volume":"59","author":"DA Volpe","year":"2011","unstructured":"Volpe DA, McMahon Tobin GA, Mellon RD, Katki AG, Parker RJ, Colatsky T, et al. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol. 2011;59(3):385\u201390.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"17","key":"2128_CR214","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1016\/j.bmc.2014.07.033","volume":"22","author":"G Weltrowska","year":"2014","unstructured":"Weltrowska G, Lemieux C, Chung NN, Guo JJ, Wilkes BC, Schiller PW. \u2019Carba\u2019-carfentanil (trans isomer): a mu opioid receptor (MOR) partial agonist with a distinct binding mode. Bioorg Med Chem. 2014;22(17):4581\u20136.","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"2128_CR215","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0022-3565(24)29358-7","volume":"298","author":"A Alt","year":"2001","unstructured":"Alt A, McFadyen IJ, Fan CD, Woods JH, Traynor JR. Stimulation of guanosine-5\u2019-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein. J Pharmacol Exp Ther. 2001;298(1):116\u201321.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"2128_CR216","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40268-019-0277-9","volume":"19","author":"R Dong","year":"2019","unstructured":"Dong R, Wang H, Li D, Lang L, Gray F, Liu Y, et al. Pharmacokinetics of sublingual buprenorphine tablets following single and multiple doses in chinese participants with and without opioid use disorder. Drugs R D. 2019;19(3):255\u201365.","journal-title":"Drugs R D."},{"issue":"11","key":"2128_CR217","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","volume":"28","author":"MK Greenwald","year":"2003","unstructured":"Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28(11):2000\u20139.","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"2128_CR218","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217371","volume":"14","author":"KM Olson","year":"2019","unstructured":"Olson KM, Duron DI, Womer D, Fell R, Streicher JM. Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids. PLoS ONE. 2019;14(6): e0217371.","journal-title":"PLoS ONE"},{"issue":"19","key":"2128_CR219","doi-asserted-by":"publisher","first-page":"6531","DOI":"10.1021\/jm2003238","volume":"54","author":"G Cami-Kobeci","year":"2011","unstructured":"Cami-Kobeci G, Polgar WE, Khroyan TV, Toll L, Husbands SM. Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine. J Med Chem. 2011;54(19):6531\u20137.","journal-title":"J Med Chem"},{"key":"2128_CR220","first-page":"440","volume":"178","author":"L Toll","year":"1998","unstructured":"Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, et al. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr. 1998;178:440\u201366.","journal-title":"NIDA Res Monogr"},{"issue":"12A","key":"2128_CR221","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/0028-3908(81)90067-8","volume":"20","author":"PL Wood","year":"1981","unstructured":"Wood PL, Charleson SE, Lane D, Hudgin RL. Multiple opiate receptors: differential binding of mu, kappa and delta agonists. Neuropharmacology. 1981;20(12A):1215\u201320.","journal-title":"Neuropharmacology"},{"key":"2128_CR222","doi-asserted-by":"publisher","first-page":"1150236","DOI":"10.3389\/fpain.2023.1150236","volume":"4","author":"EJ Santos","year":"2023","unstructured":"Santos EJ, Giddings AN, Kandil FA, Negus SS. Climbing behavior by mice as an endpoint for preclinical assessment of drug effects in the absence and presence of pain. Front Pain Res (Lausanne). 2023;4:1150236.","journal-title":"Front Pain Res (Lausanne)."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02128-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02128-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02128-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:06:02Z","timestamp":1738818362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02128-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":222,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2128"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02128-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"13 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MD has no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent (Participation and Publication)"}},{"value":"Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}